Based on Montesinos criteria (56), AG-221 investigators identified 33/281 (12%) cases of DS in IDH2-mutated R/R AML patients treated with enasidenib in the first pivotal phase 1/2 study (ClinicalTrials.gov, NCT01915498). Here, IDH2 is linked to acute myeloid leukemia.